BioLineRx Ltd. Files 6-K Reporting Press Release
Ticker: BLRX · Form: 6-K · Filed: Oct 16, 2024 · CIK: 1498403
| Field | Detail |
|---|---|
| Company | Biolinerx LTD. (BLRX) |
| Form Type | 6-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, press-release
TL;DR
BioLineRx dropped a 6-K on Oct 16th, filed a press release - check it for news.
AI Summary
BioLineRx Ltd. filed a Form 6-K on October 16, 2024, to report the issuance of a press release. The press release, filed as Exhibit 1, is incorporated by reference into the company's effective registration statements. The filing does not contain specific financial figures or operational details beyond the reporting of this press release.
Why It Matters
This filing indicates BioLineRx Ltd. has issued new information to the public, which could contain material updates relevant to investors.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain new financial data or significant operational changes.
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- October 16, 2024 (date) — Filing date and press release issuance date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report the issuance of a press release by BioLineRx Ltd. on October 16, 2024.
When was this Form 6-K filed?
This Form 6-K was filed on October 16, 2024.
What is included as Exhibit 1 to this filing?
Exhibit 1 to this filing is the press release issued by BioLineRx Ltd.
Is the press release incorporated into other filings?
Yes, the first paragraph of the press release attached as Exhibit 1 is incorporated by reference into all effective registration statements filed by the registrant.
What is the principal executive office address of BioLineRx Ltd.?
The principal executive office address of BioLineRx Ltd. is 2 HaMa’ayan Street, Modi’in 7177871, Israel.
Filing Stats: 185 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-10-16 07:08:43
Filing Documents
- zk2432149.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 12KB
- image00001.jpg (GRAPHIC) — 402KB
- 0001178913-24-003317.txt ( ) — 576KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On October 16, 2024, the Registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. The first paragraph of the press release attached to this Form 6-K as Exhibit 1 is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: October 16, 2024